Taro Pharmaceutical Industries Ltd.
TARO
TARO was delisted on the 21st of June, 2024.
109 hedge funds and large institutions have $500M invested in Taro Pharmaceutical Industries Ltd. in 2018 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 27 increasing their positions, 45 reducing their positions, and 13 closing their positions.
32% more call options, than puts
Call options by funds: $336K | Put options by funds: $255K
13% more capital invested
Capital invested by funds: $442M → $500M (+$58M)
8% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 13
0% more funds holding
Funds holding: 109 → 109 (0)
40% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 45
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$20.3M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$15M |
| 3 |
Robeco Institutional Asset Management
Rotterdam,
Netherlands
|
+$3.64M |
| 4 |
Morgan Stanley
New York
|
+$3.45M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$3.21M |
Top Sellers
TARO Hedge Fund Activity: Q2 2018 in Review
109 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q2 2018, worth a combined $500M — up 13% from $442M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new TARO positions and 13 closed out — a net gain of 1 holder — while 27 added to existing stakes and 45 trimmed.
The largest buyer was Arrowstreet Capital, adding an estimated $20.3M. The largest seller was Matthews International Capital Management, cutting an estimated $27.3M.
- 109 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $500M of Taro Pharmaceutical Industries Ltd. stock for Q2 2018, up 13% quarter-over-quarter.
- 14 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q2 2018 and 13 closed out, a net change of +1 holder.
- The largest Taro Pharmaceutical Industries Ltd. buyer in Q2 2018 was Arrowstreet Capital, an estimated $20.3M added.
- The largest Taro Pharmaceutical Industries Ltd. seller in Q2 2018 was Matthews International Capital Management, an estimated $27.3M sold.
Based on aggregated 13F filings for Q2 2018.